Akeso Stock Jumps 14.5% on AstraZeneca's $2B Investment in Partner Firm

Shares of Hong Kong-listed biotech firm Akeso Inc. (9926.HK) surged 14.5% on Tuesday, driven by news of a major investment by pharmaceutical giant AstraZeneca in one of Akeso's key international partners.

AstraZeneca Backs Summit Therapeutics

The rally was triggered after AstraZeneca disclosed a $2 billion strategic equity stake in Summit Therapeutics, a U.S.-based company. Summit holds the overseas licensing rights for several of Akeso's treatments, most notably the cancer drug ivonescimab.

AstraZeneca's investment was structured as convertible preferred stock, acquired at an approximate 18.6% premium to Summit's prior trading price. The move is being widely interpreted by investors as a strong vote of confidence in the global commercial prospects of ivonescimab, and by extension, in Akeso as the drug's original developer.

Ad

Market Impact and Context

Akeso's stock closed at HK$105.3, sharply outperforming the broader market, as Hong Kong's Hang Seng Index fell 1% during the same session. The positive sentiment also lifted other innovative drug makers in the region, creating a sympathy rally across the biotech sector.

The deal underscores a growing trend of multinational pharmaceutical companies investing in therapies originated in China, particularly in the field of bispecific antibodies. This transaction lends further credibility to Akeso's pipeline and its global out-licensing strategy. The surge also follows a period where multiple financial institutions had already issued 'Buy' ratings on the company's stock.